<p>Axsome Therapeutics, Inc.（纳斯达克代码：AXSM - 获取免费报告）在周一交易中上涨了 5.6%，因其财报超出预期。该股票最高交易价为 117.60 美元，最后交易价为 118.54 美元。在午盘交易中，共成交 231,459 股，较平均交易量 683,737 股下降了 66%。该股票此前收盘价为 112.21 美元。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>该公司报告本季度每股收益为（$0.80），超出分析师一致预期的（$1.23）$0.43。Axsome Therapeutics 的净利润率为负 74.47%，股本回报率为负 223.51%。</p>
<h2>分析师评级上调与下调</h2>
<p>AXSM 曾是多份研究报告的主题。威廉·布莱尔在 2 月 18 日的研究报告中重申了对 Axsome Therapeutics 股票的 “跑赢大盘” 评级。HC Wainwright 在 4 月 3 日的研究报告中重申了 “买入” 评级，并对 Axsome Therapeutics 股票设定了 200.00 美元的目标价。Cantor Fitzgerald 在 2 月 19 日的研究报告中重申了 “增持” 评级，并对 Axsome Therapeutics 股票设定了 153.00 美元的目标价。加拿大皇家银行在 4 月 29 日的研究报告中将 Axsome Therapeutics 股票的目标价从 190.00 美元上调至 193.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Truist Financial 在 2 月 19 日的研究报告中将 Axsome Therapeutics 股票的目标价从 190.00 美元上调至 200.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 169.87 美元。</p>
<ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p><strong>查看我们关于 Axsome Therapeutics 的最新股票报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他 Axsome Therapeutics 的新闻中，首席财务官 Nick Pizzie 在 2 月 14 日的交易中出售了 3,000 股公司的股票。股票以 131.07 美元的平均价格出售，总交易额为 393,210.00 美元。交易完成后，首席财务官现在持有 42,187 股公司股票，价值约为 5,529,450.09 美元。这笔交易代表其持股减少了 6.64%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。内部人士持有公司 22.40% 的股份。</p>
<h2>Axsome Therapeutics 的机构交易</h2>
<ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
<p>一些机构投资者最近买入和卖出了该公司的股票。Edgestream Partners L.P.在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 8,174,000 美元。纽约州共同退休基金在第一季度将其在 Axsome Therapeutics 的持股增加了 49.3%。纽约州共同退休基金目前持有 33,581 股公司股票，价值 3,917,000 美元，此前在该期间内增持了 11,090 股。美国共同资本管理公司在第一季度将其在 Axsome Therapeutics 的持股增加了 0.3%。美国共同资本管理公司目前持有 39,623 股公司股票，价值 4,621,000 美元，此前在上一季度增持了 136 股。Xponance Inc.在第一季度将其在 Axsome Therapeutics 的持股增加了 8.7%。Xponance Inc.目前持有 2,891 股公司股票，价值 337,000 美元，此前在上一季度增持了 232 股。最后，Cerity Partners LLC 在第一季度将其在 Axsome Therapeutics 的持股增加了 15.5%。Cerity Partners LLC 目前持有 5,707 股公司股票，价值 666,000 美元，此前在上一季度增持了 766 股。机构投资者持有公司 81.49% 的股份。</p>
<h2>Axsome Therapeutics 股票表现</h2>
<p>该股票市值为 58 亿美元，市盈率为-19.64，贝塔值为 0.46。该公司的债务与股本比率为 3.22，流动比率为 2.11，速动比率为 2.04。该公司的 50 日简单移动平均线为 113.58 美元，200 日简单移动平均线为 104.02 美元。</p>
<h2>关于 Axsome Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者白天过度嗜睡的药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Axsome Therapeutics</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>3 只值得关注的股票，随着比特币再次接近 10 万美元</li>
<li>电动车股票及其盈利方式</li>
<li>亚马逊：为什么伟大的反弹可能即将开始</li>
<li>3 只小型股具有巨大的回报潜力</li>
<li>3 个理由说明特斯拉应该在 6 月成为 300 美元的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>Axsome Therapeutics（纳斯达克代码：AXSM）股价上涨 5.6%，因其财报表现好于预期，最新交易价格为 118.54 美元。该公司报告的每股收益为（0.80 美元），超出市场预期的（1.23 美元）。分析师对该股票给予 “适度买入” 评级，平均目标价为 169.87 美元。机构投资者持有该公司 81.49% 的股份，近期交易活动显示出对该股票的显著兴趣。Axsome 专注于开发中枢神经系统疾病的治疗方案，产品包括 Auvelity 和 Sunosi</p>

<p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) traded up 5.6% on Monday following a better than expected earnings announcement. The stock traded as high as $117.60 and last traded at $118.54. 231,459 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 683,737 shares. The stock had previously closed at $112.21.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.（纳斯达克代码：AXSM - 获取免费报告）在周一交易中上涨了 5.6%，因其财报超出预期。该股票最高交易价为 117.60 美元，最后交易价为 118.54 美元。在午盘交易中，共成交 231,459 股，较平均交易量 683,737 股下降了 66%。该股票此前收盘价为 112.21 美元。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.23) by $0.43. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为（$0.80），超出分析师一致预期的（$1.23）$0.43。Axsome Therapeutics 的净利润率为负 74.47%，股本回报率为负 223.51%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>AXSM has been the subject of a number of research reports. William Blair restated an &#34;outperform&#34; rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Cantor Fitzgerald restated an &#34;overweight&#34; rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, April 29th. Finally, Truist Financial lifted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $169.87.</p>
<div class="lb-trans"><p>AXSM 曾是多份研究报告的主题。威廉·布莱尔在 2 月 18 日的研究报告中重申了对 Axsome Therapeutics 股票的 “跑赢大盘” 评级。HC Wainwright 在 4 月 3 日的研究报告中重申了 “买入” 评级，并对 Axsome Therapeutics 股票设定了 200.00 美元的目标价。Cantor Fitzgerald 在 2 月 19 日的研究报告中重申了 “增持” 评级，并对 Axsome Therapeutics 股票设定了 153.00 美元的目标价。加拿大皇家银行在 4 月 29 日的研究报告中将 Axsome Therapeutics 股票的目标价从 190.00 美元上调至 193.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Truist Financial 在 2 月 19 日的研究报告中将 Axsome Therapeutics 股票的目标价从 190.00 美元上调至 200.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 169.87 美元。</p>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Axsome Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Axsome Therapeutics 的最新股票报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders own 22.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Axsome Therapeutics 的新闻中，首席财务官 Nick Pizzie 在 2 月 14 日的交易中出售了 3,000 股公司的股票。股票以 131.07 美元的平均价格出售，总交易额为 393,210.00 美元。交易完成后，首席财务官现在持有 42,187 股公司股票，价值约为 5,529,450.09 美元。这笔交易代表其持股减少了 6.64%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。内部人士持有公司 22.40% 的股份。</p>
</div><h2>Institutional Trading of Axsome Therapeutics</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 的机构交易</h2>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
</div><p>A number of institutional investors have recently bought and sold shares of the company. Edgestream Partners L.P. bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at about $8,174,000. New York State Common Retirement Fund lifted its position in shares of Axsome Therapeutics by 49.3% during the 1st quarter. New York State Common Retirement Fund now owns 33,581 shares of the company's stock valued at $3,917,000 after acquiring an additional 11,090 shares during the period. Mutual of America Capital Management LLC boosted its stake in Axsome Therapeutics by 0.3% during the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company's stock worth $4,621,000 after acquiring an additional 136 shares in the last quarter. Xponance Inc. increased its position in Axsome Therapeutics by 8.7% in the 1st quarter. Xponance Inc. now owns 2,891 shares of the company's stock valued at $337,000 after buying an additional 232 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Axsome Therapeutics by 15.5% during the first quarter. Cerity Partners LLC now owns 5,707 shares of the company's stock valued at $666,000 after acquiring an additional 766 shares in the last quarter. Institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了该公司的股票。Edgestream Partners L.P.在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 8,174,000 美元。纽约州共同退休基金在第一季度将其在 Axsome Therapeutics 的持股增加了 49.3%。纽约州共同退休基金目前持有 33,581 股公司股票，价值 3,917,000 美元，此前在该期间内增持了 11,090 股。美国共同资本管理公司在第一季度将其在 Axsome Therapeutics 的持股增加了 0.3%。美国共同资本管理公司目前持有 39,623 股公司股票，价值 4,621,000 美元，此前在上一季度增持了 136 股。Xponance Inc.在第一季度将其在 Axsome Therapeutics 的持股增加了 8.7%。Xponance Inc.目前持有 2,891 股公司股票，价值 337,000 美元，此前在上一季度增持了 232 股。最后，Cerity Partners LLC 在第一季度将其在 Axsome Therapeutics 的持股增加了 15.5%。Cerity Partners LLC 目前持有 5,707 股公司股票，价值 666,000 美元，此前在上一季度增持了 766 股。机构投资者持有公司 81.49% 的股份。</p>
</div><h2>Axsome Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股票表现</h2>
</div><p>The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -19.64 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company's fifty day simple moving average is $113.58 and its two-hundred day simple moving average is $104.02.</p>
<div class="lb-trans"><p>该股票市值为 58 亿美元，市盈率为-19.64，贝塔值为 0.46。该公司的债务与股本比率为 3.22，流动比率为 2.11，速动比率为 2.04。该公司的 50 日简单移动平均线为 113.58 美元，200 日简单移动平均线为 104.02 美元。</p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>关于 Axsome Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者白天过度嗜睡的药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>3 Stocks to Watch as Bitcoin Nears $100k Again</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Amazon: Why The Great Comeback Rally Could Be About to Begin</li>
<li>3 Small Caps With Big Return Potential</li>
<li>3 Reasons Tesla Should Be a $300 Stock by June</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Axsome Therapeutics</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>3 只值得关注的股票，随着比特币再次接近 10 万美元</li>
<li>电动车股票及其盈利方式</li>
<li>亚马逊：为什么伟大的反弹可能即将开始</li>
<li>3 只小型股具有巨大的回报潜力</li>
<li>3 个理由说明特斯拉应该在 6 月成为 300 美元的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Axsome Therapeutics（NASDAQ:AXSM）股价因收益好于预期而上涨 5.6%